AGEN AGENUS INC

Nasdaq Biological Products, (No Diagnostic Substances) DE CIK: 0001098972
AI RATING
STRONG_SELL
85% Confidence

Investment Thesis

Despite impressive headline earnings growth, AGENUS shows critical financial distress: negative stockholders' equity of -$221.2M, deteriorating liquidity (0.38x current ratio), and severe cash burn (-$36.0M operating cash flow). The 116.1% net margin and $24M gap between operating and net income indicate unsustainable non-operating gains masking fundamental operational stress.

Strengths

  • + Revenue growth of 10.4% YoY shows market demand
  • + Strong operating margin of 44.6% indicates pricing power in core operations
  • + Cash position of $35.0M provides near-term runway

Risks

  • ! Negative stockholders' equity of -$221.2M: balance sheet is technically insolvent
  • ! Operating cash flow of -$36.0M: company burns cash despite positive earnings (unsustainable)
  • ! Current ratio of 0.38x: severe liquidity crisis, cannot meet short-term obligations
  • ! Interest coverage of 0.5x: cannot service debt from operations
  • ! Net income driven by non-operating items, not sustainable operations

Key Metrics to Watch

Financial Metrics

Revenue
33.7M
Net Income
39.2M
EPS (Diluted)
$1.02
Free Cash Flow
-36.0M
Total Assets
186.5M
Cash
35.0M

Profitability Ratios

Gross Margin N/A
Operating Margin 44.6%
Net Margin 116.1%
ROE N/A
ROA 21.0%
FCF Margin -106.6%

Balance Sheet & Liquidity

Current Ratio
0.38x
Quick Ratio
0.38x
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
0.48x
Long-term Debt
30.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-13T07:39:53.655218 | Data as of: 2026-03-31 | Powered by Claude AI